Terms ending in 2035
Every in-force patent on 2SEVENTY Bio, Inc.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,774,343 | MND Promoter Chimeric Antigen Receptors In force · Medium confidence | 2SEVENTY Bio, Inc. | In force | Medium confidence | |
| US 12,291,722 | Improved Methods for Manufacturing Adoptive Cell Therapies In force · High confidence | 2SEVENTY Bio, Inc. | In force | High confidence | |
| US 10,479,975 | Methods of Making T Cell Compositions In force · High confidence | 2SEVENTY Bio, Inc. | In force | High confidence | |
| US 11,479,755 | T Cell Compositions In force · High confidence | 2SEVENTY Bio, Inc. | In force | High confidence | |
| US 12,644,099 | Methods for Making T Cell Compositions In force · Medium confidence | 2SEVENTY Bio, Inc. | In force | Medium confidence | |
| US 11,530,265 | Multipartite Signaling Proteins and Uses Thereof In force · Medium confidence | Regeneron Pharmaceuticals, Inc. | In force | Medium confidence | |
| US 10,624,960 | Bcma Chimeric Antigen Receptors In force · High confidence | 2SEVENTY Bio, Inc. | In force | High confidence | |
| US 10,639,358 | Bcma Chimeric Antigen Receptors In force · High confidence | 2SEVENTY Bio, Inc. | In force | High confidence | |
| US 10,639,359 | Bcma Chimeric Antigen Receptors In force · High confidence | 2SEVENTY Bio, Inc. | In force | High confidence | |
| US 10,646,558 | Bcma Chimeric Antigen Receptors In force · High confidence | 2SEVENTY Bio, Inc. | In force | High confidence | |
| 5 more term ends in 2035 · Pro | |||||
10 of 15 patents shown. Soonest term end first, then patent number.
Pro members see all 15.
14 of these are in force and held by 2SEVENTY Bio, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.